Abstract: Anagliptin is a novel dipeptidyl peptidase-4 inhibitor that has been available in Japan since 2012. Because anagliptin is not generally used in countries other than Japan, there are only a small number of reports investigating the effects of anagliptin. In the present article, we review the safety and efficacy of anagliptin according to data obtained from preclinical trials and postmarketing studies. The usual dose of anagliptin is 200 mg daily, and increases in the dose up to 400 mg daily have been approved in cases in which the blood glucose-lowering effect is insufficient. In a Phase II trial, the reduction in the HbA 1c values from baseline after 12 weeks monotherapy with 200 mg and 400 mg of daily anagliptin was 0.75%±0.50% and 0.82%±0.46%, respectively, and more than 40% of the subjects receiving anagliptin at a dose of 200 mg or 400 mg daily achieved an HbA 1c level below 6.9%. Furthermore, the levels of HbA 1c , fasting blood glucose, and postprandial blood glucose were significantly decreased at 52 weeks compared with the baseline values in a Phase III trial investigating the effects of anagliptin included in combination therapy with other oral antidiabetic agents. In a pooled analysis of Phase II and Phase II/III trials, the goal achievement rates for an HbA 1c level below 7.0% at 12 weeks were 40.3%, 39.4%, 30.0%, and 34.8% in the patients treated with anagliptin combined with α-glucosidase inhibitors, thiazolidinediones, sulfonylureas, and biguanides, respectively. Meanwhile, the serum lipid concentrations significantly improved after the administration of anagliptin in a pooled analysis of Phase III trials, and no serious adverse effects have been reported in preclinical trials. Therefore, the use of anagliptin in patients with type 2 diabetes is considered to be safe and effective for both monotherapy and combination therapy.
Introduction
Treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors, novel oral antidiabetic agents (OADs), results in improvements in the blood glucose levels in patients with type 2 diabetes mellitus following the stimulation of endogenous insulin secretion, inhibition of glucagon release, and reduction of gastric emptying via the enhanced production of incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide). Sitagliptin, the first DPP-4 inhibitor, was approved for use by the US Food and Drug Administration in 2006 and has been available in Japan since 2009. Seven drugs belonging to this class are currently available for prescription in the clinical setting under the medical insurance law at the time of December 2014 in Japan (Table 1) .
Recent trends in the rates of antidiabetic agent prescriptions in our facility are shown in Figure 1 . While the number of patients prescribed α-glucosidase inhibitors, sulfonylureas, thiazolidinediones, and glinides has been on the decline, Notes: iC 50 , T max , T 1/2 , the inhibition of plasma DPP-4 activity, and the increase in active GLP-1 levels were based on the drug information of the corresponding agent published by the pharmaceutical company. *The dose of sitagliptin was 100 mg daily (QD 
Notes:
The data were obtained from the database of edogawa Hospital over three months. The prescription rate was calculated as the number of patients prescribed each class of antidiabetic agent divided by the total number of patients prescribed any type of antidiabetic agent. The number of patients prescribed α-glucosidase inhibitors, sulfonylureas, thiazolidinediones, and glinides has declined continuously since the release of dipeptidyl peptidase-4 (DPP-4) inhibitors. The rate of prescription of dipeptidyl peptidase-4 inhibitors increased steadily to more than 50% in 2013. in contrast, the use of insulin and biguanides has remained relatively stable at approximately 30%. Copyright ©2013. Journal of Japan Diabetes Society. Adapted from Ando S, Tsugami e, Suzuki S, et al. Recent trend in the prescription rates of antidiabetic agents in our facility. Journal of Japan Diabetes Society. 2013; 56 Suppl 1: S164.
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Abbreviations: DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1.
the rate of prescription of DPP-4 inhibitors has increased markedly in recent years, reaching 50%-60%. In contrast, the rate of prescription of insulin and biguanides has remained stable at approximately 30%. This trend is similar to that observed for data obtained from databases in Japan 1 and the United States. 2 Therefore, it is not an exaggeration to state that the introduction of DPP-4 inhibitors has changed the treatment strategies for patients with type 2 diabetes.
Metformin, an OAD in the family of biguanides, is recognized to be the first-line drug among antidiabetic agents. 3 Metformin administration is superior in the glucose-lowering effect for patients with type 2 diabetes, and regardless of the presence or absence of obesity, 4 
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Anagliptin in the treatment of type 2 diabetes remained unchanged at approximately 30% (Figure 1 ). This observation is considered to account for the relatively lower prescription rates among patients with type 2 diabetes who received consecutive treatments in our department, including many elderly subjects and individuals with renal impairment 5, 6 who are contraindicated for biguanide administration. [7] [8] [9] Patients with type 2 diabetes tend to demonstrate a decreased renal function, as indicated by the estimated glomerular filtration rate and reduced endogenous insulin secretion along with the long-term duration of diabetes and aging ( Figure 2 ). When selecting antidiabetic agents for patients with type 2 diabetes and renal dysfunction, it is necessary to use various OADs, including biguanides, sulfonylureas, and thiazolidinediones, carefully due to their side effects. On the other hand, it is a major advantage of DPP-4 inhibitors that agents in this class may be administered continuously, even in elderly subjects or patients with renal dysfunction, including those receiving maintenance dialysis. 10 Whereas linagliptin and teneligliptin do not require dose adjustment, it is recommended that the dose of other DPP-4 inhibitors is reduced depending on the degree of renal dysfunction ( 
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Nishio et al dose-dependent improvements in the HbA 1c and blood glucose levels according to the results of a Phase II trial including a dose-ranging study (50-400 mg daily), 19 increases in the dose up to 400 mg daily (200 mg, BID) have been approved. 18 In one study, the reduction in the HbA 1c values from baseline after 12 weeks monotherapy with 200 mg (n=69) and 400 mg (n=68) of daily anagliptin was 0.75%±0.50% and 0.82%±0.46%, respectively, and more than 40% of the subjects receiving anagliptin at a dose of 200 mg or 400 mg daily achieved an HbA 1c level below 6.9%. 19 In another Phase II/III trial, the administration of monotherapy for 12 weeks demonstrated a reduction of 0.66%±0.50% and 0.75%±0.55% in the HbA 1c levels with 200 mg (n=63) and 400 mg (n=58) of daily anagliptin, respectively. 20 The differences in the HbA 1c levels versus the placebo group among the subjects receiving 200 mg and 400 mg of anagliptin daily were -0.72% and -0.82%, respectively. 20 According to a pooled analysis of the data obtained from Phase II and Phase II/III trials, the goal achievement rate of an HbA 1c level less than 7.0% was 51.1% in the group treated with anagliptin at a dose of 200 mg (100 mg, BID) at 12 weeks, which was significantly superior to that attained with voglibose, an α-glucosidase inhibitor. 21 Long-term efficacy of monotherapy Kaku 17 reported that the use of monotherapy with anagliptin at a daily dose of 200 mg (with dose increases up to 400 mg permitted if the glucose-lowering effect was insufficient) showed continuous improvements in the HbA 1c levels over 52 weeks in 150 patients with type 2 diabetes whose blood glucose levels were poorly controlled (6.9%# HbA 1c ,10.5%) even after receiving nonpharmacological therapy. The changes in the HbA 1c , fasting blood glucose, and postprandial 2-h blood glucose levels were -0.63%±0.85% (baseline value: 8.22%±1.06%), -12.5±32.2 mg/dL (baseline value: 166.1±38.4 mg/dL), and -31.0±47.8 mg/dL (baseline value: 255.1±60.3 mg/dL), respectively. Furthermore, improvements were noted in the levels of 1,5-AG, glycoalbumin, serum insulin, proinsulin, homeostatic model assessment-β, total cholesterol, and low-density lipoprotein (LDL)-cholesterol.
Combination therapy
The changes in the HbA 1c levels observed in a Phase III trial 22 of anagliptin as an add-on therapy to α-glucosidase inhibitors (acarbose 20.2%, voglibose 43.6%, and miglitol 36.2%), biguanides (metformin), sulfonylureas (glimepiride 73.5%, gliclazide 10.3%, and glibenclamide 16.2%), and thiazolidinediones (pioglitazone) are shown in Table 2 . In this trial, treatment with anagliptin at a dose of 200 mg daily (100 mg, BID) or a placebo was administered for an initial 12 weeks in patients with type 2 diabetes whose HbA 1c levels were between 6.9% and 10.4%, even after treatment with other OADs. Anagliptin was subsequently administered at a dose of 200 mg daily for 40 weeks in both groups. Increases in the dose of anagliptin up to 400 mg daily (200 mg, BID) were allowed if the HbA 1c level was .6.9% at 28 weeks. Consequently, the improvements in parameters indicating glycemic control at 12 weeks were significantly greater in the anagliptin/anagliptin group than in the placebo/anagliptin group, regardless of whether OADs were administered before the trial. Furthermore, the levels of HbA 1c , fasting blood glucose, and postprandial blood glucose were significantly decreased at 52 weeks compared with the baseline values.
As it has been reported that metformin increases the plasma-active GLP-1 in humans 23 via the inhibitory effects of DPP-4, 24 combination therapy with anagliptin and metformin is considered to be suitable for the treatment of type 2 diabetes based on the enhanced endogenous GLP-1 activity. Furthermore, combination therapy with anagliptin and α-glucosidase inhibitors also has advantages, as it has been reported that GLP-1 secretion is prolonged by acarbose. 25 On the other hand, the maximum drug concentration (C max ) and area under the blood concentration-time curve (AUC) from time zero to 24 h after dosing (AUC 0-24h ) for anagliptin are reduced with the concomitant administration with miglitol, 26 whereas both the C max and AUC 0-24h values for anagliptin are elevated in subjects under treatment with the combination therapy consisting of metformin and anagliptin. 27 The degree of improvement in glycemic control achieved with combination therapy using anagliptin and sulfonylureas appears to be lower than that attained with α-glucosidase inhibitors, biguanides, or thiazolidinediones. Nevertheless, there is concern regarding the potential for hypoglycemia in patients with type 2 diabetes treated with DPP-4 inhibitors and sulfonyulureas. 28 This issue should be investigated in detail in a real clinical setting.
According to the results of a pooled analysis of the data obtained from Phase II and Phase II/III trials, 21 
Lipid-lowering effect
Managing the serum lipid concentrations is important in patients with type 2 diabetes as dyslipidemia is an important risk factor for diabetic macroangiopathy in Japanese subjects. 30 According to a pooled analysis of data obtained from Phase III trials, the serum LDL-cholesterol, triglyceride, total cholesterol and non-high-density lipoprotein (HDL)-cholesterol levels significantly improved after the administration of anagliptin at a dose of 200 mg (100 mg, BID) or 400 mg (200 mg, BID) ( Table  3) . 31 Meanwhile, the serum concentrations of HDL-cholesterol increased significantly in the subjects with an HDL-cholesterol level less than 40 mg/dL and decreased in the entire patient population. These observations suggest that there is an additional mechanism independent of the lipid-lowering effect of these drugs that occurs secondary to improvements in the blood glucose level, as the correlation coefficient between the change in the HbA 1c level and the LDL-cholesterol (r=0.112, P=0.003) or triglyceride (r=0.075, P=0.07) levels was rather small. Therefore, treatment with anagliptin is expected to prevent atherosclerotic diseases in addition to diabetic microangiopathy by improving glycemic control in patients with type 2 diabetes. 
168
Nishio et al ameliorated and the plasma level of high-molecular weight adiponectin, which has an antiatherogenic effect, increases after the initiation of therapy with 200 mg of anagliptin daily, in addition to observed improvements in blood glucose control and the serum LDL-cholesterol, triglyceride, non-HDLcholesterol and remnant-like particle-cholesterol levels. Imai et al 35 also reported that treatment with anagliptin or miglitol reduces the oral sucrose load-inducible gene expression of inflammatory cytokines, such as interleukin-1β and interleukin-18, and tumor necrosis factor-α, in the peripheral leukocytes of Otsuka Long-Evans Tokushima fatty rats. However, it remains unclear which of these anti-inflammatory effects is specifically caused by anagliptin and which occurs secondary to improvements in postprandial hyperglycemia, which is commonly seen in patients with glucose impairment.
Mimura et al 36 demonstrated that treatment with anagliptin facilitates the restoration of mucosal damage in mice exhibiting experimental colitis induced by dextran sulfate sodium. The authors suggested the possibility of applying anagliptin administration as a novel therapeutic approach for the treatment of inflammatory bowel disease. Further investigations are required to confirm this hypothesis in both basic and clinical research.
Safety and patient acceptability Safety in preclinical trials
The frequency of adverse effects (AEs) is not significantly different between subjects administered anagliptin and those administered a placebo according to the results of a Phase II trial performed over 12 weeks. 19 Most AEs were mild and no events resulting from increases in the dose of anagliptin were observed.
AEs were noted in 23.5% (19 of 81 patients) and 15.7% (11 of 70 patients) of subjects receiving preprandial and postprandial administration, respectively, during treatment with long-term monotherapy consisting of 200-400 mg of daily anagliptin (100-200 mg, BID) for 52 weeks. 17 In that study, the complications observed in more than 2% of the subjects included constipation (4.9%) and gastritis (4.9%), whereas only one patient (0.7%) showed mild hypoglycemia. Although statistically significant changes were detected in some laboratory data and vital signs compared with the baseline values, they were not considered to be meaningful due to the small variation within the normal ranges. Furthermore, no serious AEs were reported in another Phase III trial investigating the effects of combination therapy with anagliptin and other OADs. 22 Side effects observed in more than 2% of the subjects in that trial are shown in Table 4 . Because the frequency of hypoglycemia was relatively high in the sulfonylurea group, it is important to pay attention to the potential for hypoglycemia in patients receiving combination therapy with anagliptin and sulfonylureas, as described earlier.
Other than hypoglycemia, no side effects of concern have been documented. Therefore, treatment with anagliptin is considered to be superior in terms of safety and tolerability for both monotherapy and combination therapy.
Safety in the real clinical setting
One case of hypokalemia and muscle weakness was reported as serious side effects of anagliptin during postmarketing surveillance by Sanwa Kagaku Kenkyusho Co, Ltd. 37 In addition, a small number of nonserious events, including gastrointestinal symptoms (n=9) and somnolence (n=3), were observed among approximately 20,000 diabetic patients treated with anagliptin for 6 months after the drug's release. The case of a 60-year-old Japanese male with type 2 diabetes complicated by the onset of angioedema 4 days after the initiation of anagliptin was reported by Hamasaki and Yanai. 38 Although an increased risk of angioedema has been described in patients using both DPP-4 inhibitors and angiotensin-converting enzyme inhibitors, 39 no medications other than anagliptin were given in this case. Because DPP-4 influences the rate of degradation of bradykinin, the authors suggested that DPP-4 inhibitors may increase the half-life of bradykinin.
Currently, the biggest clinical concern with DPP-4 inhibitors is the increased incidence of new heart failure with these medications. 40, 41 Although alogliptin, another DPP-4 inhibitor, did not demonstrate an increased risk for cardiovascular disease and heart failure, 42, 43 there have not yet been any studies on the association between anagliptin treatment and heart failure.
Safety in patients with renal impairment
The ratio of AUC from time zero to infinity after dosing (AUC 0-∞ ) in subjects with a normal kidney function following the single administration of anagliptin at a dose of 400 mg is 1.65 ng h/mL, 1.76 ng h/mL, 2.70 ng h/mL, and 3.22 ng h/mL for those with mild renal impairment (n=6, 60 mL/ min/1.73 m 2 # creatinine clearance ,90 mL/min/1.73 m 2 ), moderate renal impairment (n=6, 30 mL/min/1.73 m 2 # creatinine clearance ,60 mL/min/1.73 m 2 ), severe renal impairment (n=6, 15 mL/min/1.73 m 2 # creatinine clearance ,30 mL/min/1.73 m 2 ), and end-stage kidney disease under maintenance hemodialysis (n=6), respectively. 18 Because AUC values are greater in the progressive stages of renal dysfunction, the dose of anagliptin is usually reduced to 100 mg once daily in patients with severe renal impairment ( Table 1 ). There are currently no studies investigating safety or patient acceptability in subjects with type 2 diabetes and renal impairment. However, treatment with anagliptin may have a glucose-lowering effect at half-doses in patients with renal dysfunction, similarly to linagliptin, 44 which does not require dose reduction.
Conclusion
Anagliptin is thought to be a potent DPP-4 inhibitor demonstrating safety and tolerability in patients with type 2 diabetes. Treatment with anagliptin improves glycemic control for both monotherapy and combination therapy, and it is possible that anagliptin prevents atherosclerotic disease as well as diabetic 
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Nishio et al microangiopathy. However, there are too few reports of the effects of anagliptin. There is currently no data on the use of this drug for more than 1 year or the application of combination therapy with anagliptin and insulin. Additionally, the antiatherogenic effect of anagliptin was not supported by any comprehensive clinical data. Further investigation is therefore necessary to clarify the safety, efficacy, and patient acceptability of anagliptin in subjects with type 2 diabetes.
